To further characterize the TME, we performed gene expression analysis of tumors from Prf1+/+ and Prf1–/–MMTV-PyMT mice treated with either vehicle or SnMP for 36 hours, using the NanoString nCounter platform with the Pan-Cancer Immune Profiling Panel (Figure 3, A–F). The gene discussed is PRF1; the disease is cancer.